JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2017, 66(2):76-82 | DOI: 10.36290/csf.2017.010

Targeted drug delivery system: potential application to resveratrol

Hassan Farghali, Ludmila Kameníková*
Farmakologický ústav 1. LF UK a VFN, Praha

Drug delivery system (DDS) is intended to increasing effectiveness of drugs through targeted distribution and to reducing of unwanted effects. In this mini-review, the basic principles of nanotechnology that were developed for DDS were reported including sections on the present research in key areas that are important for future investigations. Attention is paid on resveratrol as a model phytochemical with interesting pharmacologic profile which was demonstrated in great numbers of studies and for its wide use as supplemental therapy. Due to complicated pharmacokinetic profile of resveratrol that is characterized by very low bioavailability in spite of high oral absorption, the effects of resveratrol is being studied in new nanotechnology preparations of pharmaceutical formulation.
Herein we report on results of present in vitro and in vivo investigations with resveratrol in new types of drug formulations using different nanoparticles as liposomes, solid lipid particles, cyclodextrins and micelles.

Keywords: targeted drug delivery; nanotechnology; resveratrol

Received: April 14, 2017; Accepted: May 11, 2017; Published: February 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Farghali H, Kameníková L. Targeted drug delivery system: potential application to resveratrol. Čes. slov. farm. 2017;66(2):76-82. doi: 10.36290/csf.2017.010.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Král V. Život je geniální projekt. Za obzorem Vyd. Advent Orion s.r.o., 2013; 1, 1-4.
    2. Pamornpathomkul B., Wongkajorsilp A., Laiwattanapaisal W., Rojanarata T., Opanasopit P., Ngawhirunpat T. A combined approach of hollow microneadles and nanocarriers for skin immunization with plastid DNA encoding ovalbumin. Int. J. Nanomedicine 2017; 12, 885-898. Go to original source... Go to PubMed...
    3. Gusta S., Wilder H., Rao A. L. N., Vyllev V. I., Anvari B. Plant virus-resembling optical nano-materials conjugated with Anti-EGFR for targeted cancer imaging. Reporters, dyes, nanoparticles, and molecular probes for biomedical applications IV. 2012; Proceedings of SPIE vol. 8233, No. 82330S. Go to original source...
    4. Hwang S. R., Ku S. H., Joo M. K., Kim S. H., Kwon I. C. Theranostic nanomaterials for image-guided gene therapy. MRS Bulletin 2014; 39, 44-50. Go to original source...
    5. Neves A. R., Lúcio M., Martins S., Lima J. L., Reis S. Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int. J. Nanomedicine 2013; 8, 177-187. Go to original source... Go to PubMed...
    6. Summerlin N., Soo E.,Thakur S., Qu Zhi. Resveratrol nanoformulations: Challenges and opportunities. Inter. J. Pharmac. 2015; 479, 282-290. Go to original source... Go to PubMed...
    7. Aluyen J. K., Ton Q. N., Tran T., Yang A. E., Gottlieb H. B., Belanger R. A. Resveratrol potential as anticancer agents. J. Diet Supl. 2012; 9, 45-56. Go to original source... Go to PubMed...
    8. Kraft T. E., Parisotto D., Schempp C., Efferth T. Fighting cancer with red wine? Molecular mechanisms of resveratrol. Crit. Rev. Food Sci. Nutr. 2009; 49, 782-799. Go to original source... Go to PubMed...
    9. Yang X., Li X., Ren J. From french paradox to cancer treatment: anti-cancer activities and mechanisms of resveratrol. Anti-Cancer Agents Med. Chem. 2014; 14, 806-825. Go to original source... Go to PubMed...
    10. Farghali H., Kutinová Canová N., Lekic N. Resveratrol and related compounds as antioxidants with an allosteric mechanism of action in epigenetic drug targets. Physiol. Res. 2013; 2, 1-13. Go to original source... Go to PubMed...
    11. Vang O., Ahmad N., Baile C. A., Baur J. A., Brown K., Csiszar A., Das D. K., Delmas D., Gottfried C., Lin H. Y. What is new for an old molecule? Systematic Review and Recommendations on the use of resveratrol. Plos One 2011; 6, No. E9881, doi:10.1371. Go to original source...
    12. Augustin M. A., Sanguansri L., Lokett T. Nano- and micro-encapsulated systems for enhancing the delivery of resveratrol. Ann. N.Y. Acad. Sci. 2013; 1290, 107-112. Go to original source... Go to PubMed...
    13. Walle T. Biovailability of resveratrol. Ann. N.Y. Acad. Sci. 2011; 1215, 9-15. Go to original source... Go to PubMed...
    14. Rotches-Ribalta M., Andres-Lacueva C., Estruch R., Escribano E., Urpi-Sarda M. Pharmacokinetic of resveratrol metabolic profile in healty humans after moderate consumption of red wine and grape extrakt tablets. Pharmacol. Res. Off. J. Ital. Pharmacol. Soc. 2012; 66, 375-382. Go to original source... Go to PubMed...
    15. Brown V. A., Patel K. R., Viskaduraki M., Crowell J. A., Perloff M., Booth T. D., Vasilinin G., Sen A., Schinas A., Piccirilli G., Brown K., Steward W. P., Gescher A. J., Brenner D. E. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis.Cancer Research 2010; 70, 9003-9011. Go to original source... Go to PubMed...
    16. Almeida L., Vaz-da-Silva M., Falcao A., Soares E., Costa R., Loureiro A. J., Fernandes-Lopes C., Rocha J. P., Nunes T., Wright L., Soares-da-Silva P. Pharmacokinetic and safety profile of trans-resveratrol in a Rosiny multiply-dose study in healthy volunteers. Mol. Nutr. Food Res. 2009; 53, S7-15. Go to original source... Go to PubMed...
    17. Boocock D. J., Faust G. E. S., Patel K. R., Schinas A. M., Brown V. A., Duchařme M. P., Booth T. D., Crowell J. A., Perloff M., Gescher A. J., Steward W. P., Brenner D. E. Phase I dose escalation pharmacokinetic study in healthy volunteer of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers and Prevention 2007; 16, 1246-1252. Go to original source... Go to PubMed...
    18. Rotches-Ribalta M., Andres-Lacueva C., Estruch R., Escribano E., Urpi-Sarda M. Pharmacokinetic of resveratrol metabolic profile in healty humans after moderate consumption of red wine and grape extrakt tablets. Pharmacol. Res. Off. J. Ital. Pharmacol. Soc. 2012; 66, 375-382. Go to original source... Go to PubMed...
    19. Karthikeyan S., Rajendra Prasat N., Ganamani A., Balamurugan E. Anticancer aktivity of resveratrol-loaded gelatin nanoparticles on NCI-H460 non-small cell lung cancer cells. Biomed. Prev. Nutr. 2013; 3, 64-73. Go to original source...
    20. Miki H., Uehara N., Kimura A., Sasaki T., Yuri T., Yoshizawa K., Tsubura A. Resveratrol induces apoptosis via ROS-triggered autophagy in human colon cancer cells. Int. J. Oncol. 2012; 40, 1020-1028. Go to original source... Go to PubMed...
    21. Sun W., Wang W., Kim J., Keng P., Yang S., Zhang H., Liu C., Okunieff P., Zhang L. Anti-cancer effect of resveratrol is associated with induction of apoptosis via a mitochondrial pathway alignment. Adv. Exp. Med. Biol. 2008; 614, 179-186. Go to original source... Go to PubMed...
    22. Sengottuvelan M., Deeptha K., Nalini N. Resveratrol ameliorates DNA damage, prooxidant and antioxidant imbalance in 1,2-dimethylhydrazine induced rat colon carcinogenesis. Chem. Biol. Interact. 2009; 181, 193-201. Go to original source... Go to PubMed...
    23. Murias M., Jager W., Handler N., Erker T., Horvath Z., Szekeres T., Nohl H., Gille L. Antioxidant, prooxidant and cytotoxic aktivity of hydroxylated resveratrol analogues: structure-activity relationship. Biochem. Pharmacol. 2005; 69, 903-912. Go to original source... Go to PubMed...
    24. Richard T., Pawlus A. D., Iglesias M. I., Pedrot E., Waffo-Teguo P., Merillon J. M., Monti J. P. Neuroprotective properties of resveratrol and derivatives. Ann. N. Y. Acad. Sci. 2011; 1215, 103-108. Go to original source... Go to PubMed...
    25. Yaseen A., Chen S., Hock S., Rosato R., Dent P., Dai Y., Grant S. Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway. Mol. Phamacol. 2012; 82, 1030-1041. Go to original source... Go to PubMed...
    26. Sinico C., Pirredu R., Pini E., Valenti D., Caddeo C., Fadda A. M., Lai F. Enhancing topíval delivery of ŕesveratrol through nanosizing approach. Planta Medica 2017; 83, 476-481. Go to original source... Go to PubMed...
    27. da Rocha Lindner G., Khalil N. M., Mainardes R. M. Resveratrol-loaded polymeric nanoparticles: validation of an HPLC-PDA method to determine the drug entrapment and evaluation of its antioxidant aktivity. Sci. World J. 2013; 2013, S06083. Go to original source... Go to PubMed...
    28. Venuti V., Cannava C., Cristiano M. C., Fresta M., Majolino D., Paolino D., Stancanelli R., Tommasini S., Ventura C. A. A characterization study od resveratrol/sulfobutyl ether-beta-cyklodextrin inclusion complex and in vitro anticancer activity. Colloids Surf. B Biointerfaces 2014; 115, 22-28. Go to original source... Go to PubMed...
    29. Maeda H., Bharate G. Y., Daruwalla J. Polymeric drugs for efficient tumor- targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm. 2009; 71, 409-419. Go to original source... Go to PubMed...
    30. Allen T. M., Cullis P. R. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 2013; 65, 36-48. Go to original source... Go to PubMed...
    31. Coimbra M., Isacchi B., van Bloois L., Torano J. S., Ket A., Wu X., Broere F., Metselaar J. M., Rijcken C. J., Storm G., Bilia R., Schiffelers R. M. Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes. Int. J. Pharm. 2011; 416, 433-442. Go to original source... Go to PubMed...
    32. Csiszar A., Csiszar A., Pinto J. T., Gautam T., Kleusch C., Hoffmann B., Tucsek Z., Toth P., Sonntag W. E., Ungvari Z. Resveratrol encapsulated in novel fusogenic liposomes activates Nrf2 and attenuates oxidative stress in cerebromicrovascular endothelial cells from aged rats. J. Gerontol. Series A. Biol. Sci. Med. Sci. 2014; 70, 303-313. Go to original source... Go to PubMed...
    33. Catania A., Barrajon-Catalan E., Nicolosi S., Cicirata F., Micol V. Immunoliposome encapsulation increases cytotoxic aktivity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells. Breast Cancer Res. Treat. 2013; 141, 55-65. Go to original source... Go to PubMed...
    34. Barrajon-Catalan E., Menendez-Gutierrez M. P., Falco A., Carrato A., Saceda M., Micol V. Selective death of human breast cancer cells by lytic immunoliposomes: correlation with their HER2 expression level. Cancer Lett. 2010; 290, 192-203. Go to original source... Go to PubMed...
    35. Wang X. X., Li Y. B., Yao H. J., Ju R. J., Zhang Y., Li R. J., Yu Y., Zhang L., Lu W. I. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomaterials 2011; 32, 5673-5687. Go to original source... Go to PubMed...
    36. Mohan A., Narayanan S., Sethuraman S., Krishnan U. M. Novel resveratrol and 5-fluorouracil coencapsulated in PEGylated nanoliposomes improve chemotherapeutic efficacy of combination against head and neck squamous cell carcinoma. BioMed. Res. Int. 2014; Artical Numer 424239. Go to original source...
    37. Singh G., Pai R. S. Optimized PLGA nanoparticle platform for orally dosed trans-resveratrol with enhanced bioavailability potential. Exp. Opin. Drug Deliv. 2014; 11, 647-659. Go to original source... Go to PubMed...
    38. Sanna V., Siddiqui I. A., Sechi M., Mukhtar H. Resveratrol-loaded nanoparticles based on poly(epsilon-caprolactone) blend for prostate cancer treatment. Mol. Pharm. 2013; 10, 3871-3881. Go to original source... Go to PubMed...
    39. Guo W., Li A., Jia Z., Juan Y., Dai H., Li H. Transferrin modified PEG-PLA-resveratrol conjugates: in vitro and in vivo studies for glioma. Eur. J. Pharmacol. 2013; 718, 41-47. Go to original source... Go to PubMed...
    40. Yin H., Si J., Xu H., Dong J., Zheng D., Lu X., Li X. Resveratrol-loaded nanoparticles reduce oxidative stress induced by radiation or anuloid-beta in transgenic Caenorhabditis elegans. J. Biomed. Nanotechnol. 2014; 10, 1536-1544. Go to original source... Go to PubMed...
    41. Xu W., Ling P., Zhang T. Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. J. Drug Deliv. 2013; 20, 340315. Go to original source... Go to PubMed...
    42. Kim S., Shi Y., Kim J. Y., Park K., Cheng J. X. Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle cell interaction. Exp. Opin. Drug Deliv. 2010; 7, 49-62. Go to original source... Go to PubMed...
    43. Ekambaram P., Sathali A., Priyanka K. Solid lipid nanoparticles: a review. Sci. Rev. Chem. Commun. 2012; 2, 80-102.
    44. Teskac K., Kristl J. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int. J. Pharm. 2010; 390, 61-69. Go to original source... Go to PubMed...
    45. Jose S., Anju S. S., Cinu T. A., Aleykutty N. A., Thomas S., Souto E. B. In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery. Int. J. Pharm. 2014; 474, 6-13. Go to original source... Go to PubMed...
    46. Lu Z., Chen R., Fu R., Xiong J., Hu Y. Cytotoxicity and inhibition of lipid peroxidation activity of resveratrol/cyclodextrin inclusion complexes. J. Incl. Phenom. Macrocycl. Chem. 2012; 73, 313-320. Go to original source...
    47. Tiwari G., Tiwari R., Rai A. Cyclodextrins in delivery systems: applications. J. Pharm. Bioallied Sci. 2010; 2, 72-79. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.